Market Place
Sourcing Support
Relmada Therapeutics Reports 2025 Results And Business Update
19 Mar 2026 //
GLOBENEWSWIRE
Relmada Therapeutics To Release Q4 2025 Financial Results
12 Mar 2026 //
GLOBENEWSWIRE
Relmada Therapeutics Unveils 12-Month Phase 2 Interim Data
09 Mar 2026 //
GLOBENEWSWIRE
Relmada Therapeutics To Present At Global Healthcare Conference
09 Mar 2026 //
GLOBENEWSWIRE
Relmada Raises $160M in Oversubscribed Private Placement
09 Mar 2026 //
GLOBENEWSWIRE
Relmada, FDA Agree on NDV-01`s Registrational Study Design
12 Jan 2026 //
GLOBENEWSWIRE
Relmada Therapeutics Presents NDV-01 Phase 2 Data at SUO
03 Dec 2025 //
GLOBENEWSWIRE
Relmada Therapeutics To Release Q3 2025 Financial Results
07 Nov 2025 //
GLOBENEWSWIRE
Relmada Pharma Prices $100M Stock Offering & Pre-Funded Warrants
04 Nov 2025 //
GLOBENEWSWIRE
Relmada Appoints Dr. Max Kates To Advance NDV-01 To Phase 3
13 Oct 2025 //
INDPHARMAPOST
Relmada Pharma Appoints Urologic Oncologist Max Kates
07 Oct 2025 //
GLOBENEWSWIRE
Relmada Restores Nasdaq Minimum Bid Price Compliance
16 Sep 2025 //
GLOBENEWSWIRE
Relmada`s Mid-Year CEO Letter to Shareholders Released
10 Sep 2025 //
GLOBENEWSWIRE
Relmada Reports Q2 2025 Financial Results
07 Aug 2025 //
GLOBENEWSWIRE
Relmada Appoints Yair to Chair Clinical Advisory Board
15 Jul 2025 //
GLOBENEWSWIRE
Relmada Dumps Depression Asset After Slew of Phase 3 Failures
14 Jul 2025 //
FIERCE BIOTECH
Relmada Therapeutics to Report Q1 2025 Results on May 12
08 May 2025 //
GLOBENEWSWIRE
Relmada Therapeutics Presents Positive Phase 2 Data at AUA2025
28 Apr 2025 //
GLOBENEWSWIRE
Relmada Therapeutics To Present NDV-01 Data at AUA2025
27 Apr 2025 //
GLOBENEWSWIRE
Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data
24 Apr 2025 //
GLOBENEWSWIRE
Relmada Therapeutics To Present NDV-01 Data at AUA2025
14 Apr 2025 //
GLOBENEWSWIRE
Relmada Therapeutics Licenses Bladder Cancer Candidate NDV-01
25 Mar 2025 //
GLOBENEWSWIRE
Relmada Acquires Tourette Syndrome Therapy from Asarina Pharma
06 Feb 2025 //
GLOBENEWSWIRE
Relmada Discontinues Reliance II & Relight Phase 3 Studies
09 Dec 2024 //
GLOBENEWSWIRE
Relmada Reports Futility of Ph 3 Trial at Interim Analysis
04 Dec 2024 //
GLOBENEWSWIRE
Relmada To Present At Jefferies London Healthcare Conference
19 Nov 2024 //
GLOBENEWSWIRE
Relmada Doses 1st Patient with REL-P11 for Metabolic Disease
14 Nov 2024 //
GLOBENEWSWIRE
Relmada Therapeutics Reports Q3 2024 Financial Results & Update
07 Nov 2024 //
GLOBENEWSWIRE
Relmada Reports Q3 2024 Financials & Business Update
07 Nov 2024 //
PR NEWSWIRE
Relmada Therapeutics to Report Q3 2024 Results on Nov 7
04 Nov 2024 //
GLOBENEWSWIRE
Relmada Therapeutics Reports Q2 2024 Results And Business Update
07 Aug 2024 //
GLOBENEWSWIRE
Relmada Therapeutics To Report Q2 2024 Results On August 7
05 Aug 2024 //
GLOBENEWSWIRE
After phase 3 flops, Relmada plots depression drug comeback
25 Mar 2023 //
FIERCE BIOTECH
